The feasibility of personalized and tumor-informed ctDNA assay for early recurrence detection in post-liver transplantation patients with hepatocellular carcinoma.

作者：Maen Abdelrahim, Alejandro Mejia, Abdullah Esmail, Juan Carlos Barrera-Gutierrez, Mahmoud Ouf, Joseph W. Franses, Irun Bhan, Sudha Kodali, Ashish Saharia, Amit Mahipal, Nikolas Naleid, Catherine Bridges, Antony Tin, Chris M. Brewer, Vasily N. Aushev, Arkarachai Fungtammasan, Adham Jurdi, Minetta C. Liu, Rafik M. Ghobrial, Aiwu Ruth He · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco.2025.43.16_suppl.e16283 · 被引用次数：2 · 研究领域：Cancer Genomics and Diagnostics、Hepatocellular Carcinoma Treatment and Prognosis、Organ Transplantation Techniques and Outcomes

e16283 Background: Hepatocellular carcinoma (HCC) has a high likelihood of relapse following standard-of-care (SOC) resection or liver transplantation (LT). This study explored the role of circulating tumor DNA (ctDNA) in predicting relapse or progression in HCC patients. Methods: We conducted a real-world analysis of ctDNA data from 125 HCC patients (721 plasma samples) undergoing curative-intent treatment. The cohort was divided into four subgroups: Cohort A (N = 64) and Cohort B (N = 52) included patients under recurrence surveillance post-LT or resection, respectively. Cohort C (N = 4) and Cohort D (N = 5) involved patients monitored for treatment response, with known recurrence or inoperable disease, respectively. All patients received SOC management, including AFP testing. A personalized, tumor-informed 16-plex PCR-NGS assay (SignateraTM, Natera, Inc.) was employed for ctDNA analysis. The molecular residual disease (MRD) period was defined as 2-12 weeks post-LT or resection (Cohorts A and B) before initiating adjuvant therapy (AT). The surveillance period was designated as after the MRD window or 2 weeks post-AT (Cohort B), or during ongoing treatment (Cohorts C and D). Results: The cohort had a median follow-up of 40 months (range: 1.5 - 60). In Cohort A, 97.2% (35/36) of patients with negative ctDNA during the MRD window remained negative in subsequent surveillance. In Cohort B, ctDNA was detected in 29.4% (10/34) of patients during the MRD window, all of whom experie...